Library Subscription: Guest
Begell Digital Portal Begell Digital Library eBooks Journals References & Proceedings Research Collections
Critical Reviews™ in Therapeutic Drug Carrier Systems
IF: 2.9 5-Year IF: 3.72 SJR: 0.736 SNIP: 0.551 CiteScore™: 2.43

ISSN Print: 0743-4863
ISSN Online: 2162-660X

Volumes:
Volume 36, 2019 Volume 35, 2018 Volume 34, 2017 Volume 33, 2016 Volume 32, 2015 Volume 31, 2014 Volume 30, 2013 Volume 29, 2012 Volume 28, 2011 Volume 27, 2010 Volume 26, 2009 Volume 25, 2008 Volume 24, 2007 Volume 23, 2006 Volume 22, 2005 Volume 21, 2004 Volume 20, 2003 Volume 19, 2002 Volume 18, 2001 Volume 17, 2000 Volume 16, 1999 Volume 15, 1998 Volume 14, 1997 Volume 13, 1996 Volume 12, 1995

Critical Reviews™ in Therapeutic Drug Carrier Systems

DOI: 10.1615/CritRevTherDrugCarrierSyst.2017018714
pages 1-64

Polymeric Immunonanoparticles Mediated Cancer Therapy: Versatile Nanocarriers for Cell-Specific Cargo Delivery

Namdev L. Dhas
Institute of Pharmacy, Nirma University, Ahmedabad, Gujarat, India
Ritu R. Kudarha
Faculty of Pharmacy, The Maharaja Sayajirao University of Baroda, Vadodara, Gujarat, India
Niyati S. Acharya
Institute of Pharmacy, Nirma University, Ahmedabad, Gujarat, India
Sanjeev R. Acharya
SSR College of Pharmacy, Sayli, Silvassa, Dadra Nagar and Haveli, India

ABSTRACT

The major drawback with conventional therapeutic approaches for cancer therapy is decreased efficacy and redundant therapy associated toxicity and side effects causing increased patient discomfort. With the aim of minimizing these limitations, a vast amount of attention has been given to targeted nanocarrier–based drug delivery systems that possess a several-fold advantage over conventional therapy. Increased research in targeted nanoparticulate systems has led to the development of immunonanoparticles with enhanced efficacy and targeting efficiency along with decreased drug-resistant cancer- and dose-related toxicity. These immunonanoparticle- based therapies, which can be extended to immunotherapy, have gained wide attention, but few formulations will be approved by regulatory agencies in the near future. This review details the various immunonanoparticle systems explored in cancer therapy, with particular emphasis on polymeric nanoparticles. This review describes the mechanisms of immunotherapy and the pathways for targeting dendritic cells for immunotherapy. It also focuses on present status of clinical trials of immunonanoparticles and related patents, as well as various FDA-approved monoclonal antibodies (mAbs) for immunotherapy. Toxicity issues related to immunonanoparticles along with regulatory guidelines for these therapeutic nanoparticles are also discussed.


Articles with similar content:

Progress in Lipid-Based Nanoparticles for Cancer Therapy
Critical Reviews™ in Oncogenesis, Vol.19, 2014, issue 3-4
Eliahu Heldman, Charles Linder, Sarina Grinberg
Intranasal Delivery of Nanotherapeutics/ Nanobiotherapeutics for the Treatment of Alzheimer's Disease: A Proficient Approach
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.36, 2019, issue 5
Namdev L. Dhas, Tejal A. Mehta, Ritu R. Kudarha
Nanosuspensions in Drug Delivery: Recent Advances, Patent Scenarios, and Commercialization Aspects
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.28, 2011, issue 5
Krutika Sawant, Kailash C. Petkar, Sandip S. Chavhan
Nanomedicines for Treatment of Viral Diseases
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.30, 2013, issue 1
Medha Joshi, Vandana B. Patravale, Rujuta Mehendale
Long-Acting Injectables: Current Perspectives and Future Promise
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.36, 2019, issue 2
Komal Chaudhary, Mayur M. Patel, Priti J. Mehta